Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and LSM-4272

moxifloxacin has been researched along with LSM-4272 in 1 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(LSM-4272)		Trials
(LSM-4272)		Recent Studies (post-2010) (LSM-4272)
3,1575521,69015012

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)LSM-4272 (IC50)
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus9.96
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 29.96
Cyclin-dependent kinase 4Homo sapiens (human)0.35
G1/S-specific cyclin-D1Homo sapiens (human)0.35
G1/S-specific cyclin-E1Homo sapiens (human)0.35
Cyclin-dependent kinase 2Homo sapiens (human)0.35

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW1

Other Studies

1 other study(ies) available for moxifloxacin and LSM-4272

ArticleYear
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
    Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23

    Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors

2021